Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
1 citations
,
January 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
12 citations
,
June 2013 in “The Prostate” Dutasteride and finasteride affect different cell types differently.
October 2023 in “Biomedical science and engineering” Innovative methods are reducing animal testing and improving biomedical research.